Theraclion secures financing via a convertible bond issue

Theraclion has announced the issuance of a convertible bond of up to €6 million, reserved for its historical shareholders, Furui and Unigestion. The aim is to improve the company's financial structure to support its development strategy and research.

Investors have committed to subscribe to €3 million of convertible bonds by the end of 2025. This financing targets commercial expansion, research and development, and FDA approval in the United States. Technological innovations, such as the 'SpeedPulse', are currently undergoing clinical testing.

This operation should also allow expansion into the European and Middle Eastern markets. Theraclion hopes to reach a turnover of 2.5 million euros in 2025 and 5 million in 2026.